OSI Looks To CRO To Develop Oncologic Agent Following Pfizer Divestiture
Executive Summary
OSI Pharmaceuticals is planning to turn development of its oncologic CP-358,774 over to a contract research organization following termination of OSI's development collaboration with Pfizer.
You may also be interested in...
Pfizer On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 2 of 2)
On the way back to his old job in the U.S., after a stint in Shanghai as head of research in Asia, VP Richard Connell, head of Preclinical Outsourcing says Pfizer is “pausing” plans for an anti-infectives research unit in China after hitting a few speed bumps.
First Horizon Pharmaceuticals’ Cognex (correction)
First Horizon owns Alzheimer's disease agent Cognex; company purchased rights from Warner-Lambert in 2000 ahead of the Pfizer merger (1"The Pink Sheet" June 26, 2000, p. 20). "The Pink Sheet" incorrectly reported the product as a Pfizer drug in the Oct. 20 issue...
First Horizon Pharmaceuticals’ Cognex (correction)
First Horizon owns Alzheimer's disease agent Cognex; company purchased rights from Warner-Lambert in 2000 ahead of the Pfizer merger (1"The Pink Sheet" June 26, 2000, p. 20). "The Pink Sheet" incorrectly reported the product as a Pfizer drug in the Oct. 20 issue...